Research funding

16-26849S - Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy (2016-2018)
20-20414Y - Study on the role of novel targeted breast and lung anticancer drugs in the phenomenon of pharmacokinetic drug resistance (2020 – 2022)

114909/C – Study of interactions of CDK inhibitors with ABCG2 (BCRP) drug transporter (2009 – 2011)
137010/C – Localization and function of organic cation transporter 3 (OCT3) in the rat placenta (2010 – 2012)
700912/C – Study of interactions of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter (2012 – 2014)
1568218/C - Interactions of novel anticancer drugs with ABC drug efflux transporters and cytochromes P450; their role in multidrug resistance (2018 – 2020)
334120/C - The role of pharmacokinetic interactions of new targeted drugs in the modulation of efficacy of cytotoxic drugs in non-small cell lung carcinoma (2020 – 2022)
102121/C - Implementation of ex vivo and in vivo lung tumor models for the evaluation of clinical value of dual drug resistance modulators (2021-2023)

INOMED - Pre-application research into innovative medicines and medical technologies, OP VVV programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds (2019-2022)
PRIMUS 20/MED/010 - Farmakokinetické mechanizmy lékové rezistence u akutní myeloidní leukémie, jejich ovlivnění a regulace, Charles University (2020-2022)
START/MED/070 - Unraveling pharmacodynamic principles of acquired resistance to epidermal growth factor receptor inhibitors, Charles University (2021-2023)